#### **Medi-Cult case**

Objective: Evaluate alternative pricing strategies to enter multiple markets with a new product innovation

#### Q1) Calculate the economic value of IVM, considering the features, benefits and differentiation between IVM and IVF

**Table A: Cost for IVF Cycle** 

	Cost of IVF Treatment (a)	Cost of Hormones 1 (b) Lab Work (c)		
USA	\$4,000-\$6,000	\$3,000	\$500	
Rest of the World	\$2,000-\$3,000	\$1,500	\$300	

<sup>1</sup> The hormones are usually directly purchased by the patient at a pharmacy while the rest of the costs (IVF treatment, lab work, etc.) are billed to the patient or alternative payer by the hospital 2 Miscellaneous costs include additional doctor visits, ultrasound monitoring, workdays lost, and hospitalization. Note: this cost varies as hormone injections affect some women more than of treatment.)

#### Table A: Cost for IVM Cycle

	Cost of IVF Treatment (a)	Cost of Hormones 1 (b) Lab Work (c)	
USA	\$4,000-\$6,000	\$300	\$250
Rest of the World	\$2,000-\$3,000	\$150	\$150

<sup>1</sup> These costs reflect the various steps of IVF treatment such as the initial doctor visit, tests, egg aspiration, fertilization, and embryo transfer which still have to be performed with the IVM. It

<u>USA Market</u> <u>Rest of the World</u>

## **Reference Price**

sufficient for 1 cycle \$50
No of cycles for child birth 3 to 5
Stimulation 30 days

No of injections	Upto 50 injections	
Women experiencing Nausea	50%	
Women experiencing sickness	10%	
hospitaliztion	2%	
Cost of IVF Treatment	\$5000	\$2500
Positive Differential Value		
No Hormonal injections required		
Cost of Hormones	\$300.00	\$150.00
Lab Work	\$250.00	\$150.00
Miscellaneous Cost	\$250.00	\$100.00
Total PDV	\$800.00	\$400.00
Negative Differential Value	0	0

Misc. Costs <sup>2</sup> (d)	101AL COS1 (a+h+c+d)
\$500	\$8,000-\$10,000
\$200	\$4,000-\$5,000

al/clinic.

hers.

Misc. Costs <sup>2</sup> (d)	101AL COS1 (a+h+c+d)
\$250	\$4,800-\$6,800
\$100	\$2,400-\$3,400

however does not include the cost of Medi-Cult's IVM maturation medium.

Medi-Cult would be marketing IVM medium in the form of a single dose sufficient for one cycle. In addition, the company would be providing training, upgrading, technology development, and quality control to the clinics involved. Medi-Cult planned to produce IVM like any other IVF medium, and had calculated the cost to produce a single dose of IVM medium to be slightly more expensive than its current cost of producing IVF medium.

Note: I have assumed that we will not be needing IVF Medium for IVM Cycle and that the cost of IVM Medium and IVF Medium is similar

Price + PDV - NDV

## Q1) Assess the price sensitivity of demand for IVM in each country. How does elasticity differ from country to country and why does it matter?

						Potential	Price Points(USD)
			High Price	_			Medium Price
Country	Respondent	Price	Volume	Market Share	Price Sensitivity	Price	Volume
Denmark	Kristen Krag, Int'l Sales Director	1875	325	5.00%	1.75	1562.5	500
France	Denis Azra, General Manager	1428.57	500	1.50%	0.38	892.86	650
UK	Lesley Hutchins, General Manager	1500	2,000	8.00%	1.17	1166.67	3,000
USA	Larry Fava, General Manager	2200	1,200	1.50%	0.00	1600	1,200

price

#### **Summary:**

#### Denmark

increasing by more than double when they reduced the price. reimburses upto 70% of hormone and medication cost

#### France

share increasing from 2% to a mere 3% when they reduced the price. cost  $% \left( 1\right) =\left( 1\right) ^{2}$ 

#### UK

market share increasing from 12% to 16% when they reduced the price. decreasing from 12% to 8% when they increased the price.

treatment and this may be the cause for moderate price sensitivity

## USA

the higher price

prices or lowering prices will help us achieve our pricing objectives

)								
	Low Price							
Market Share	Price	Volume	Market Share	Price Sensitivity				
7.00%	1250	1,200	17.00%	7.00				
2.00%	714.29	900	3.00%	1.92				
12.00%	833.33	4,000	16.00%	1.17				
1.50%	1000	1,200	1.50%	0.00				

Exhibit 4
Results of IVM Pricing Exercise

					Pote	ntial Price F	oints
			High Price		Medium Price		
Country	Respondent	Price <sup>1</sup>	Volume <sup>2</sup>	Market Share <sup>3</sup>	Price	l Volume	Market Share
Denmark	Kristen Krag, Int'l Sales Director	DKK 12,000	325	5.00%	DKK 10,000	500	7.00%
France	Denis Azra, General Manager	FF 8,000	500	1.50%	FF 5,000	650	2.00%
UK	Lesley Hutchins, General Manager	£900	2,000	8.00%	£700	3,000	12.00%
USA	Larry Fava, General Manager	\$2,200	1,200	1.50%	\$1,600	1,200	1.50%

	_	Potential Price Points(USD)			ts(USD)		
			High Price M		Medium Price		
Country	Respondent	Price <sup>1</sup>	Volume <sup>2</sup>	Market Share <sup>3</sup>	Price	Volume	Market Share
Denmark	Kristen Krag, Int'l Sales Director	1875	325	5.00%	1562.5	500	7.00%
France	Denis Azra, General Manager	1428.57	500	1.50%	892.86	650	2.00%
UK	Lesley Hutchins, General Manager	1500	2,000	8.00%	1166.67	3,000	12.00%
USA	Larry Fava, General Manager	2200	1,200	1.50%	1600	1,200	1.50%

<sup>1</sup> Price for a single dosage sufficient for one cycle

- 2 Estimated number of IVM cycles for the first 12 months
- 3 Percentage of total number of IVF cycles within that country

# **Currency Exchange Rates:**

US\$1 = FF 5.6 (French francs)

US\$1 = £0.60 (British pounds)

US\$1 = DKK 6.4 (Danish krone)

## Exhibit 3

## **Estimated Number of IVF Cycles/Year**

### Europe

Lurope	
France	33,000
Germany	30,000
Italy	27,000
UK	25,000
Benelux	15,000
Spain	13,000
Sweden	10,000
Denmark	7,000
Norway	4,000
Finland	4,000

168,000

North America 90,000

USA 80,000 Canada 10,000

Rest of the world 87,000

TOTAL CYCLES WORLDWIDE 345,000

	Low Price	
Price	Volume	Market Share
DKK 8,000	1,200	17.00%
FF 4,000	900	3.00%
£500	4,000	16.00%
\$1,000	1,200	1.50%

Low Price						
Price		Volume	Market Share			
	1250	1,200	17.00%			
7	14.29	900	3.00%			
8:	33.33	4,000	16.00%			
\$	1,000	1,200	1.50%			